Company

Sickle-Cell Setback Or Acquisition Setup? Agios’ 48% Drop Could Draw Dealmakers

Agios plunged 48% after its Phase III Pyrukynd trial delivered mixed results, missing key pain-crisis and fatigue endpoints. Despite strong hemoglobin gains, AGIO still seeks FDA approval. ...

Priority Technology Turmoil: Shareholder Revolt Explodes Over CEO’s Low-Ball Takeover Bid

Priority Tech faces turmoil as major holder Steamboat blasts the CEO’s go-private bid as too low. With improving results and the CEO controlling 50%+, a high-stakes valuation fight is now ...

Sprout Social Jumps on M&A Chatter — What the Adobe Rumors Really Mean!

Sprout Social drew attention after takeover rumors linked Adobe to a possible bid. Strong 13% revenue growth, record margins, and AI traction fuel speculation, but no official moves yet ahead ...

Voyager Technologies Just Bought Estes—Here’s Why It Could Redefine Missile Defense!

Voyager’s acquisition of Estes Energetics boosts vertical integration in missile tech, aligning with DoD priorities and strengthening supply-chain control, but high costs and execution risks remain. ...

Kaltura Goes All-In on Avatars & AI — Will eSelf Make or Break Them?

Kaltura is making waves after agreeing to buy eSelf.ai for $27M, a move that accelerates its shift from video SaaS to an AI-driven CX and EX platform powered by real-time, ...

Alphabet’s Race Toward a $4 Trillion Valuation Signals a New Phase of AI Dominance

Alphabet is approaching a $4 trillion market value after a recent surge that reshaped investor expectations for the future of AI as well as the entire tech sector. ...

Pacira BioSciences Pops As Activist Investor Calls For Sale — What You Need To Know!

Pacira jumped into M&A chatter after investor DOMA Perpetual urged a full sale, arguing the biotech could fetch $66/share. Activist pressure follows solid EXPAREL growth but weak stock performance. ...

Braskem Shares Soar: Could This Be the Comeback Moment for the Debt-Laden Giant?

Braskem jumped after a $230M settlement eased major legal risk and reports of IG4 Capital seeking control sparked hopes for debt relief, stronger governance, and a long-awaited turnaround. ...

Exodus Just Bought Grateful—Here’s How It Could Disrupt Stablecoin Payments

Exodus’ acquisition of Grateful adds stablecoin payments, merchant tools, and global expansion potential, helping the company move toward a broader financial superapp despite execution risks. ...

Avadel Stock Soars As Lundbeck Outbids Alkermes—Will A Bidding War Break Out?

Lundbeck’s higher $23 bid lifts Avadel’s near-term upside and sparks talk of a bidding war, but its non-binding terms, CVR risks, and the board’s support for Alkermes leave the outcome ...

TreeHouse Foods Just Scored A Major Deal—But Is It Worth $2.9 Billion?

Investindustrial’s bid sent TreeHouse Foods soaring as the PE firm targets its margin-expansion plan, private-label growth, strong cash flow, and discounted valuation—despite recent weak results. ...

Intellia Therapeutics Loses A Patient & $BILLIONS In Value — Can It Recover?

Intellia plunged after a patient died in its ATTR trial, prompting FDA holds on two Phase III studies and raising serious questions about safety, CRISPR risks, and the future of ...